Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Geldart

P1.13-17 Multicentre Phase II Trial of First-Line Afatinib in Patients With Suspected/Confirmed EGFR Mutant NSCLC: ctDNA and Long-Term Efficacy

Journal of Thoracic Oncology

English

Related publications

P1.13-26 First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant NSCLC Patients With Oligoprogressive Disease

Journal of Thoracic Oncology

English

First-Line Osimertinib in Patients With Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC

Journal of Thoracic Oncology

English

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

Wspolczesna Onkologia

English

P3.13-10 Factors Associated With Long-Term Survival of Stage IV NSCLC Patients on First-Line EGFR-Targeting Therapy

Journal of Thoracic Oncology

English

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

P3.13-15 First-Line Afatinib Dose Initiation and Adjustment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology

English

P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC With Progression on Prior EGFR-TKI

Journal of Thoracic Oncology

English

157P Second-Line Afatinib for Patients With Locally Advanced or Metastatic NSCLC Harbouring Common EGFR Mutations: A Phase IV Study

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Geldart

P1.13-17 Multicentre Phase II Trial of First-Line Afatinib in Patients With Suspected/Confirmed EGFR Mutant NSCLC: ctDNA and Long-Term Efficacy

Related publications

P1.13-26 First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant NSCLC Patients With Oligoprogressive Disease

First-Line Osimertinib in Patients With Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

P3.13-10 Factors Associated With Long-Term Survival of Stage IV NSCLC Patients on First-Line EGFR-Targeting Therapy

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

P3.13-15 First-Line Afatinib Dose Initiation and Adjustment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC With Progression on Prior EGFR-TKI

157P Second-Line Afatinib for Patients With Locally Advanced or Metastatic NSCLC Harbouring Common EGFR Mutations: A Phase IV Study